GlassScriptPhysician profile
Jeffrey M Okun
NPI 1063730794
$3,947.59
in general payments reported to CMS, 2019-2025
22 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $130 · 2021: $595 · 2022: $289 · 2023: $778 · 2024: $919 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.10 |
| Education | $190.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $769.62 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $346.29 | 2023-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $312.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $255.73 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $207.05 | 2024-2025 | Voquezna |
| Pfizer INC. | $206.20 | 2019-2025 | |
| Genzyme Corporation | $179.88 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.24 | 2020-2025 | Entyvio |
| Allergan, INC. | $158.59 | 2019 | |
| Braintree Laboratories, INC. | $102.60 | 2019-2025 | Suflave, Sutab |
| Endogastric Solutions, INC | $82.71 | 2023 | Esophyx |
| Qol Medical, LLC | $62.24 | 2024-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $58.53 | 2019-2023 | Rebyota |
| Medtronic, INC. | $35.88 | 2023 | Minimed 780g |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $29.21 | 2024 | |
| Merck Sharp & Dohme LLC | $29.00 | 2023 | Dificid, Zinplava |
| Gilead Sciences, INC. | $23.92 | 2021 | |
| Ardelyx, INC. | $19.00 | 2025 | Ibsrela |
| Lilly USA, LLC | $18.51 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $14.38 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Okun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.